Key Takeaways for Neratinib Plus T-DM1 Combination in Breast Cancer
Jame Abraham, MD, discusses the key takeaways from the phase Ib study of trastuzumab emtansine in combination with neratinib in patients with HER2-positive breast cancer.
Jame Abraham, MD, professor of medicine at the Cleveland Clinic and co-director of the Cleveland Clinic Comprehensive Breast Cancer Program, discusses the key takeaways from the phase Ib study of trastuzumab emtansine (T-DM1) in combination with neratinib (Nerlynx) in patients with HER2-positive breast cancer.
First, Abraham says that the trial shows T-DM1 is an active regimen in combination with neratinib for patients who progress or are refractory to trastuzumab (Herceptin) and pertuzumab (Perjeta). With a dose of neratinib at 160 mg, the combination had deep responses in this patient population.
